Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 6/20 | 0.59 |
| ▸ | CNR2 | P34972 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12697368 | 0.84 | FAAH (0.61) | CNR2KMT2AFAAHHPGDSMN1; SMN2 | |
| SCHEMBL12472334 | 0.84 | EGLN1 (0.64) | EGLN1KMT2ALMNAMAPT | |
| SCHEMBL12697416 | 0.82 | CNR2 (0.56) | CNR2KMT2AFAAHHPGDLMNA | |
| SCHEMBL12697382 | 0.81 | EGLN1 (0.79) | EGLN1KMT2ARPS6KB1 | |
| SCHEMBL12697309 | 0.81 | FAAH (0.57) | CNR2KMT2AFAAHHPGDSMN1; SMN2 | |
| SCHEMBL16977703 | 0.78 | LIPG (0.55) | CNR2KMT2AFAAHHPGDSMN1; SMN2 | |
| SCHEMBL2353779 | 0.78 | EGLN1 (0.60) | EGLN1KMT2ACNR1SMN1; SMN2HTT | |
| SCHEMBL12697379 | 0.78 | CNR2 (0.65) | CNR2KMT2AFAAHCNR1HPGD | |
| SCHEMBL12697380 | 0.78 | ALDH1A1 (0.55) | EGLN1CNR2KMT2AHPGDSMN1; SMN2 | |
| SCHEMBL2201315 | 0.74 | EGLN1 (1.00) | EGLN1KMT2AHPGDSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150218120-A1 | HIV INTEGRASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-08-06 | — | — | US | disclosed |
| US-20140142137-A1 | HIV INTEGRASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (US) | 2014-05-22 | — | — | US | disclosed |
| WO-2012106534-A2 | HIV INTEGRASE INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142137-A1 | HIV INTEGRASE INHIBITORS | IMPDH1, TYMP, IMPA1 | EGLN1 2462/4885CNR2 4787/4885KMT2A 1460/4885 |
| US-20150218120-A1 | HIV INTEGRASE INHIBITORS | IMPDH1, TYMP, IMPA1 | EGLN1 2462/4885CNR2 4787/4885KMT2A 1460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.